Abstract:
New immunological carrier systems, DNA encoding the same, and the use of these systems, are disclosed. The carrier systems include chimeric proteins which include a leukotoxin polypeptide fused to one or more selected GnRH multimers which comprise at least one repeating GnRH decapeptide sequence, or at least one repeating unit of a sequence corresponding to at least one epitope of a selected GnRH molecule. Under the invention, the selected GnRH sequences may all be the same, or may correspond to different derivatives, analogues, variants or epitopes of GnRH so long as the GnRH sequences are capable of eliciting an immune response. The leukotoxin functions to increase the immunogenicity of the GnRH multimers fused thereto.
Abstract:
The Mig protein gene of Streptococcus dysgalactiae, and the corresponding amino acid sequence, is described, as is the use of the Mig protein in vaccine compositions to prevent and treat bacterial infections in general, and mastitis in particular.
Abstract:
Cloning and expression of genes encoding H. somnus transferring-binding proteins are described. The transferrin-binding proteins can be used in vaccine compositions for the prevention and treatment of H. somnus infections, as well as in diagnostic methods for determining the presence of H. Somnus infections.
Abstract:
L'invention a pour objet de nouvelles protéines et des antigènes de sous-groupes provenant de P. haemolytica, s'utilisant pour stimuler l'immunité contre des maladies respiratoires comme la pneumonie, y compris la pneumonie causée par le transport. Les antigènes de sous-groupes comprennent des séquences immunogènes amino-acides de la protéine periphérifine de P. haemolytica, de la proteine réceptrice de plasmine de P. haemolytica et de la protéine de membrane extérieure 50 K de P. haemolytica ainsi que de la leucotoxine de P. haemolytica. Les antigènes peuvent s'utiliser dans une composition de vaccin, soit seuls soit en combinaison. L'invention se rapporte également à des procédés de vaccination ainsi qu'à des procédés de production des antigènes de sous-groupes
Abstract:
Compositions and methods for stimulating an immune response against a secreted enterohemorragic Escherichia coli (EHEC) antigen are disclosed. The compositions comprise EHEC cell culture supernatants.
Abstract:
Compositions and methods for stimulating an immune response against Shiga toxin-producing Escherichia coli (STEC) antigens are disclosed. The compositions include a multiple epitope fusion protein comprising more than one epitope of an immunogenic STEC protein from more than one STEC serotype. Additional compositions include at least two purified STEC proteins, wherein the STEC proteins are selected from a full-length STEC protein, an immunogenic fragment or variant thereof, wherein at least one of the STEC proteins generates antibodies that react with STEC O157 and at least one other STEC serotype.
Abstract:
The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.
Abstract:
The CAMP factor gen of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. CAMP factors can be used in vaccine compositions for the prevention and treatment of bacterial infections.
Abstract:
Novel Haemophilus somnus immunogenic proteins are disclosed. The proteins can be used in vaccine compositions for the prevention and treatment of H. somnus infections. The proteins are conveniently produced using recombinant technology.